Latham & Watkins Advises the Underwriters in Landos Biopharma’s Initial Public Offering

Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, has announced the pricing of its initial public offering of 6,250,000 shares of common stock at the public offering price of US$16 per share, for total gross proceeds of US$100 million, before deducting underwriting discounts and commissions and offering expenses payable by Landos Biopharma. All of the shares of the common stock are being offered by Landos Biopharma.

Latham & Watkins LLP represents the underwriters in the offering with a capital markets team led by New York partner Nathan Ajiashvili, with associates Salvatore Vanchieri, Matthew DeSilva, and Daniel Walder.